Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$15.62B
Positions
98
New
8
Increased
16
Decreased
6
Sold Out
5
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $15.62B across 98 positions in their Q1 2019 SEC 13F filing (period ending 2019-03-31). The top 10 positions account for 85.5% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $3.74B | 23.93% | +0.0% |
| 2 | INCYIncyte Corporation | $2.95B | 18.87% | +0.1% |
| 3 | ONCBeiGene, Ltd. | $1.58B | 10.11% | - |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $1.16B | 7.41% | +0.0% |
| 5 | ACADACADIA Pharmaceuticals Inc. | $1.07B | 6.83% | - |
| 6 | Amarin Corporation plc | $897.05M | 5.74% | +1.5% |
| 7 | GHDXGenomic Health, Inc. | $714.44M | 4.57% | -13.2% |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $674.16M | 4.32% | - |
| 9 | ASNDUSDAscendis Pharma A/S | $399.04M | 2.55% | +19.5% |
| 10 | MRTXEURMirati Therapeutics, Inc. | $184.24M | 1.18% | - |
| Stock | Value | Shares |
|---|---|---|
| AXSMAxsome Therapeutics, Inc. | $17.08M | 1,200,000 |
| DERMEURDermira, Inc. | $12.29M | 906,943 |
| MGNXMacroGenics, Inc. | $5.44M | 302,600 |
| PTGXProtagonist Therapeutics, Inc. | $5.08M | 403,893 |
| PTGXProtagonist Therapeutics, Inc. | $5.08M | 403,893 |
| Acorda Therapeutics, Inc. | $3.88M | 292,134 |
| CTMXCytomX Therapeutics, Inc. | $2.09M | 194,377 |
| Harpoon Therapeutics, Inc. | $2.03M | 214,285 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.